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Transcriptomic changes following chronic administration of 
selective serotonin reuptake inhibitors: a review of animal 
studies
The review focuses on transcriptomic changes following treatment with serotonin reuptake 
inhibitor (SSRI) antidepressants. We aimed to overview results of the most established meth-
ods for the investigation of the gene expression alterations including northern blotting, in 
situ hybridization, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), 
microarray and RNAseq in various brain regions and after chronic treatment protocols. 
In spite of some measurable changes in serotonin system mRNA expression, serotonin 
transporter levels remained mostly unaltered following various treatment protocols. In 
contrast, tryptophan hydroxylase 2 appeared to be downregulated in serotonergic nuclei, 
and upregulated in the midbrain regions. Alterations in serotonin receptors lack clear con-
clusions and changes probably reflect animal strain/substance related- and brain region 
dependent effects. Brain derived neurotrophic factor was upregulated following many, but 
not all chronic treatment regimens. GABA and glutamate genes also showed heterogeneous 
changes, with a surprising NMDA receptor downregulation in areas including the striatum 
and amygdala, known to be involved in depressive states and stress reactions. The review 
of the above studies suggests alterations in multiple processes, reflecting the heterogene-
ity of the action depending on brain area and type of SSRI, and raises the possibility of a 
novel grouping of antidepressant medications based on their chronic molecular profile 
rather than on their initial actions. 
(Neuropsychopharmacol Hung 2019; 21(1): 26–35)
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INTRODUCTION
Antidepressants (ADs) are on the market since the 
1950s and in wide use since the 1960s for the treat-
ment of depression. Following tricyclic antidepres-
sants (TCAs) and monoamine oxidase inhibitors as 
the first antidepressants, selective serotonin reuptake 
inhibitors (SSRIs) have been introduced towards the 
end of the 1980s in an attempt to employ antidepres-
sants with more selective action mechanisms to limit 
burdensome side effects, but retaining therapeutic 
efficacy. Subsequently several other groups of antide-
pressants were introduced based on the monoamine 
theory of depression aimed at selectively targeting 
one or more of such systems, including for example 
serotonin–norepinephrine reuptake inhibitors (SN-
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RIs) and norepinephrine reuptake inhibitors (NRIs). 
Nevertheless, SSRIs remain the most prescribed 
medications for the treatment of major depressive 
disorders (Bobo et al. 2019).
Major depressive disorder (MDD) is a complex 
and heterogeneous disorder both in its manifesta-
tion and in its neurobiology, and accordingly, the 
pathogenesis can’t be easily determined. Genetic, 
environmental and biological factors together play a 
role in the development of depression (see for review 
(Gonda et al. 2019). 
The acute mechanism of action of the SSRIs con-
stitutes the blockade of the serotonin transporter di-
rectly elevating serotonin concentration in the syn-
aptic cleft which, together with a similar blockade 
of noradrenaline reuptake, was thought to be the 
primary mechanism responsible for antidepressant 
effects ever since the observation that tricyclic anti-
depressants block these transporters (Coppen 1967; 
Schildkraut 1965). While this theory is not up to 
date, the monoaminergic systems remained in the 
focus of antidepressant pharmacotherapy, and a more 
complex mechanism of how monoaminergic antide-
pressants influence neurotransmitter function have 
been described. 
Functional effects after the administration of 
SSRIs are diverse and biphasic, also reflected in the 
temporal development of both side effects and ther-
apeutic effects in the course of treatment. The mo-
lecular changes underlying these functional effects 
can be measured by gene expression analysis (Volle 
et al. 2018). Four common methodical approaches 
are used to identify alterations of gene expression 
including northern blot, in situ hybdridization (ISH), 
quantitative reverse transcription polymerase chain 
reaction (qRT-PCR), RNA microarrays and RNA se-
quencing (RNA-Seq). 
In this review, after a short overview on current 
methods in gene expression analysis we summarize 
animal studies assessing transcriptomic changes fol-
lowing chronic SSRI administration. 
METHODS FOR GENE EXPRESSION ANALYSIS
Northern blot
Northern blotting is one of the oldest methods in 
analyzing gene expression. Electrophoresis is used to 
separate the RNAs of the sample by size with a very 
low throughput, usually after separation of those with 
a polyA tail (mRNAs) from the other RNA content 
(Kevil et al. 1997). Then, the mRNA containing gel 
has to be transferred onto a nylon membrane with 
the help of the electrophoretic blotter. Under UV light, 
the RNAs of different sizes will be covalently bound 
to this membrane. Afterwards, oligomers, usually of 
complementary DNA sequences (transcribed from 
RNA with reverse transcriptase) will be used for hy-
bridization to the RNA of interest. After washing out, 
the hybridization, which is from the labelled oligonu-
cleotides sequences or probes being complementary 
to the target transcript, will be detected by X-Ray. 
In this way, northern blot is useful to determine the 
RNA transcript size and also its sequence through the 
probes (VanGuilderet al. 2008). In northern blotting, 
a larger amount of RNA compared to qRT-PCR is 
required and is much less sensitive with respect to 
mRNA expression compared to qRT-PCR (Fehr et 
al. 2000).
In situ hybridization 
In situ hybridization is a method using labelled DNA 
or RNA probes which can attach selectively to the 
nucleic acid of interest even in a cellular environment, 
thus, for example in a brain sample. Advantage of the 
method is the information about the specific cellular 
localization of the transcript and the fine (or even 
manual) evaluation of the signals that can provide 
additional details about the expression patterns (see 
e.g. Kirilly et al. 2008). The method is, nevertheless, 
unfeasible for transcriptional analysis on a larger 
scale. 
qRT-PCR
Real-Time Quantitative Reverse Transcription PCR 
(polymerase chain reaction) is a method based on 
PCR. First RNA will be converted to cDNA with the 
use of reverse transcriptase. After this step the expo-
nential amplification of cDNA takes place with PCR. 
A specific primer, or probe, will be attached on the 
template cDNA strand in order to start the replication 
trough polymerase enzyme. A probe is a modified 
primer with for example a fluorescent molecule (Heid 
et al. 1996), allowing relative quantification of specific 
genes, through sensors at a certain wavelength, during 
each PCR cycle (Cooper 2000).
Thus with this method, it is possible to quantify 
multiple genes with a high throughput single reac-
tion. Trancriptome-wide gene expression analysis is 
however difficult (in case of some animal species), or 
even absolutely unfeasible (e.g. in humans) to realize 
(Teo et al. 2016).
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Microarray
In differential expression analysis RNA is purified, 
extracted and is transcribed to cDNA. After tran-
scription, cDNA samples are labeled with different 
fluorescent colors and applied on the microarray 
chip. The microarray chip is already printed with 
short, complementary probes of genes of interests 
and, thus, the cDNAs hybridize with these comple-
mentary sequences on the chip. Gene expression can 
be identified and compared through the different 
fluorescent intensity on the chip (Trevinoet al. 2007). 
Microarrays has been the technology of choice for 
large-scale studies of gene expression, since it is pos-
sible to measure the gene expression of thousands of 
known or putative transcripts or even genome-wide 
transcription simultaneously (Teo et al. 2016).
RNA-seq
RNA sequencing is the newest method for gene 
expression analysis and uses the next generation 
sequencing (NGS) platform. The main advantage 
of this method is the massively parallel sequencing 
and thus the possibility of detailed and transcrip-
tome-wide analysis. There are several methods to 
perform RNA-seq that are different in their sequenc-
ing and amplification steps. From RNA, cDNA will 
be transcribed and will be cut randomly into more 
or less equally sized fragments. Fragments are ligated 
with sequence adaptors and amplified. For example, 
in case of Illumina platforms, amplification is made 
through bridge amplification on so-called flow cells, 
which create clusters of the same DNA fragments on 
the flow cell (www.illumina.com). After amplification 
the fragments are sequenced to produce reads. Again, 
in Illumina platforms this is based on the sequential 
addition of labelled bases that upon integration in the 
synthesis of the strand emit light, which is detected 
by a camera after each step. Thus, millions of cDNA 
copies are sequenced by synthesis in parallel. The 
number of cycles determines the read length. After-
wards in silico analysis is performed by various tools, 
the first step in the analysis pipeline is to map reads to 
a known reference genome. Which software exactly 
has to be used to map and align the reads depends on 
the sequencing protocol (sequencing data type). In 
RNA-seq for example the tool Tophat is used for the 
alignment (D’Antonio et al. 2015; Al Seesi et al. 2016). 
The next step depends on the scientific question. With 
different tools it is possible for example to identify 
chimeric transcripts, splicing junctions or alternate 
splicing in addition to differential gene expression 
analysis. The advantage of RNA-seq is that the whole 
transcriptome can be analyzed and discovery of novel 
transcripts is also possible (Teo et al. 2016).
TRANSCRIPTOMIC CHANGES FOLLOWING 
SSRI ADMINISTRATION
There have been several studies focusing on transcrip-
tomic changes following SSRI administration. Since 
antidepressants are taken long-term and not acute 
for their therapeutic effects to manifest, an investiga-
tion with a single dose may not reflect the long-term 
gene expression changes. Therefore, in our review 
we confined our research on transcriptomic changes 
after chronic in vivo treatments in animals (rats, if 
not stated otherwise). Genetically modified animals 
were excluded (except one study for a particular sero-
tonin receptor) as they could not represent the whole 
spectrum of targets.
Effects of chronic SSRI administration on 
expression of genes involved serotonin synthesis 
and serotonin transport 
The prime acute target of SSRIs is the serotonin trans-
porter (5-HTT). Nevertheless, 5-HTT mRNA levels 
were unaffected in the hippocampus after four weeks 
of citalopram (CIT) (10mg/kg) and fluoxetine (FLX) 
(10mg/kg) treatments (Cardamone et al. 2014). The 
same result was demonstrated after 12 d FLX (10mg/
kg) treatment in the dorsal raphe (DRN) (Volle et 
al. 2018), after 21d treatment with FLX (3mg/kg) 
(Neumaier et al. 1996) and 4 week-long CIT (30mg/
kg) treatment in the same region (Abumaria et al. 
2007). Another study reported different results in the 
midbrain and brainstem after 2, 4 and 8 week-long 
treatments with FLX (7,5mg/kg), showing decreased 
5-HTT expression (Shishkina, Kalinina, and Dygalo 
2007). 
Other studies focused on tryptophan hydroxylase 
2 (TPH2) expression, which is the rate limiting en-
zyme in serotonin synthesis. A recent human study 
reported significantly decreased TPH2 mRNA ex-
pression in MDD patients who also attempted suicide 
(Zhang et al. 2015). The authors linked decreased 
TPH2 expression with DNA methylation of the TPH2 
promoter region in MDD patients. In rat studies, FLX 
(7,5mg/kg) administration normalized the mRNA ex-
pression of TPH2 in the midbrain of stressed rodents 
(Shishkina et al. 2007). In the rat studies, following 
four-week CIT (30mg/kg) treatment downregulation 
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of TPH2 in the DRN was reported (Abumaria et al. 
2007) and decreased expression in the brainstem was 
also observed in case of a two week long FLX (25mg/
kg) treatment (Dygalo et al. 2006). Based on the above, 
changes in TPH2 expression following chronic SSRI 
treatment appear to be heterogeneous and no clear 
conclusions can be drawn. For detailed results see 
Table 1.
Effect of chronic SSRI administration  
on expression of serotonin receptor genes
While mainly the 5HT1A receptor has been empha-
sized in the action of SSRIs, the serotonin receptor 
family includes 14 receptors (Segi-Nishida 2017), 
some of which showed expression changes following 
chronic SSRI administration. During SSRI treatment 
the negative feedback mechanism limiting the sero-
tonin release is inactivated due to the desensitization 
of the raphe 5-HT1A (and partially the 5-HT1B) au-
toreceptors that changes the discharge of serotoner-
gic neurons (Hamon and Blier 2013). This process 
is assumed to take several weeks. Cardamone et al. 
(2014) reported no change in 5-HT1A expression 
after a four week long FLX treatment in the HC of 
rats while 5HT1A receptor upregulation was observed 
in the same time period and region following CIT 
(10mg/kg) treatment. We have to note that in this 
study rats underwent kindling to investigate kindling 
epileptogenesis and the effects of ADs in this process, 
which might have influenced mRNA expression (Car-
damone et al. 2014). 
Surprisingly, no expression changes were detect-
ed in the raphe nuclei after FLX (10mg/kg) for 12 
days (Volle et al. 2018), while 5-HT1A mRNA was 
downregulated after 28 day-long treatment with CIT 
(30mg/kg) (Abumaria et al. 2007). Thus, studies show 
contradictory results on 5HT1A expression both in 
the HC and DRN. It is possible that different medica-
tions, treatment protocols, strains, and methodologies 
used to identify gene expression are responsible for 
these contradictory findings. Interestingly, desensi-
tized 5HT1A receptors in the DRN, without a change 
in the receptor levels after FLX (Le Poul et al. 1995) 
and sertraline (SER) (Rossi et al. 2008) treatment, 
were observed in healthy rodents (Le Poul et al. 1995; 
Rossi et al. 2008). 
The serotonin 1B receptor (5-HT1B) is located 
mainly presynaptically locally regulating 5-HT re-
lease [for review see (Sari 2004)]. It is possibly im-
plicated in the pathophysiology of MDD. For ex-
ample, a combination of a 5HT1B antagonist and 
a SSRI showed a rapid antidepressant effect (Sari 
2004). 5-HT1B mRNA expression of rats in DRN was 
downregulated following 21 days of FLX (3mg/kg) 
treatment while no changes were observed in the ra-
phe nuclei after 12 days of FLX (10mg/kg) treatment 
(Neumaier et al. 1996; Volle et al. 2018). The exper-
iment from (Neumaier et al. 1996) also reported no 
significant 5-HT1B expression changes in the frontal 
cortex, striatum or HC. Another research team inves-
tigating this receptor in rats found decreased levels of 
5-HT1B mRNA in the DRN with FLX (5mg/kg) and 
SER (10mg/kg) after eight week-long administrations, 
Table 1  Expression changes in serotonin transporter and synthesis
Medication Region Species Method Time Daily dose Result Reference
FLX HC Wistar rat PCR 28 d 10mg/kg 5-HTT 0 (Cardamone et al. 2014)
CIT HC Wistar rat PCR 28 d 10mg/kg 5-HTT 0 (Cardamone et al. 2014)
FLX DR Sprague Dawley rat ISH 12 d 10mg/kg 5-HTT 0 (Volle et al. 2018)
CIT DRN Wistar rat PCR 28 d 30mg/kg 5-HTT 0 (Abumaria et al. 2007)
FLX DRN Sprague Dawley rat ISH 21 d 3mg/kg 5-HTT 0 (Neumaier et al. 1996)
FLX Midbrain Wistar rat PCR 14, 28 and 56 d 7,5mg/kg 5-HTT  (Shishkina et al. 2007)
FLX Brainstem Wistar rat PCR 14, 28 and 56 d 7,5mg/kg 5-HTT  (Shishkina et al. 2007)
CIT DRN Wistar rat PCR 28 d 30mg/kg TPH2  (Abumaria et al. 2007)
FLX Midbrain Wistar rat PCR 4 and 8 weeks 7,5mg/kg TPH2  (Shishkina et al. 2007)
CIT DRN Wistar rat PCR 28 d 30mg/kg TPH2  (Abumaria et al. 2007)
FLX Brainstem Wistar rat PCR 14 d 25mg/kg TPH2  (Dygalo et al. 2006)
HC: Hippocampus; DR: Dorsal raphe; DRN: Dorsal raphe nucleus; 0: no changes observed; : upregulation observed; : downregulation 
observed
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while paroxetine (PXT) (5mg/kg) treatment for 56 
days didn’t contribute to any significant decrease in 
5-HT1B expression in this region. All three SSRIs 
failed to alter 5-HT1B expression in the HC (Anthony 
et al. 2000). 
The serotonin 2C receptor (5-HT2C) has been im-
plicated as a potential target of therapeutic efforts for 
various psychiatric disorders (Higgins and Fletcher 
2003). Elevated protein levels of 5-HT2C in suicide 
victims was demonstrated in the prefrontal and fron-
tal cortices when compared to controls (Pandey et 
al. 2006). MRNA levels were postmortem increased 
in patients with schizophrenia and bipolar disorder 
(Castensson et al. 2003; Iwamoto and Kato 2003). In a 
rat experiment using FLX (10 mg/kg) administration, 
5-HT2C showed a downregulation in the prefrontal 
cortex (P/FC) and elevated mRNA levels were detect-
ed in the HC (Barbon et al. 2011). 
A (partial) agonism at the serotonin 4 receptors 
(5HT4) showed rapid effects on depression-related 
behaviors and on hippocampal neurogenesis sug-
gesting a possible role in MDD (Mendez-David et al. 
2014; Vidal et al. 2014). Since transcriptomic changes 
are lacking in the literature, we discuss here, as an 
exception a study with transgenic mice. This exper-
iment revealed that chronic treatment in transgenic 
mice with FLX elevated 5HT4 receptor expression 
levels in cortical neurons (Schmidt et al. 2012). P11 
is a protein product of the S100a10 gene and has been 
involved in the mediation of antidepressant responses 
and depression-like states (Svenningsson 2006). Cor-
tical neurons express p11 and 5HT4 receptors and 
may have behavioral effects in concert with SSRIs 
[we recommend reading (Schmidt et al. 2012) for 
further information about the connection between 
p11 and 5-HT4]. 
Besides the ones described above, there are other 
serotonin receptors with possible roles in depression 
and antidepressant pharmacotherapy that lack tran-
scriptomic data following SSRI treatments, which 
is not to say that they couldn’t be of etiological or 
therapeutic importance. Some papers, for example, 
mention the 5HT6 and 5HT7 receptors as useful tar-
gets in the treatment of affective disorders (Carr et al. 
2011; Nikiforuk 2015). For an overview of the studies 
discussed above see Table 2.
Effect of chronic SSRI treatment on expression  
of neuroplasticity factors
Brain-derived neurotrophic factor (BDNF) is widely 
implicated both in the etiopathology of depression 
and in the mechanism of its treatment. BDNF stimu-
lates neuroplasticity during development and also in 
adulthood (Huang and Reichardt 2001; McAllister et 
al. 1999). Deficits in neuroplasticity factors can lead 
to depression (Fossati et al. 2004). Decreased BDNF 
levels may be a factor for depression, and in a me-
ta-analysis decreased serum BDNF was suggested to 
be a relevant biomarker in MDD patients (Polyakova 
et al. 2015). Several studies showed an upregulation 
while others showed no effect on BDNF levels with 
different SSRIs [for a review see (Duman and Mon-
teggia 2006)]. 
Table 2  Expression changes in the serotonin transporter and its receptors
Medication Region Species Method Time Daily dose Result Reference
FLX HC Wistar rat PCR 28 d 10mg/kg 5HT1A 0 (Cardamone et al. 2014)
CIT HC Wistar rat PCR 28 d 10mg/kg 5HT1A  (Cardamone et al. 2014)
FLX Raphe nuclei Sprague Dawley rat ISH 12 d 10mg/kg 5HT1A 0 (Volle et al. 2018)
CIT DRN Wistar rat PCR 28 d 30mg/kg 5HT1A  (Abumaria et al. 2007)
FLX Raphe nuclei Sprague Dawley rat ISH 12 d 10mg/kg 5HT1B 0 (Volle et al. 2018)
FLX DRN Sprague Dawley rat ISH 21 d 3mg/kg 5HT1B  (Neumaier et al. 1996)
FLX DRN Sprague Dawley rat ISH 56 d 5mg/kg 5HT1B  (Anthony et al. 2000)
SER DRN Sprague Dawley rat ISH 56 d 10mg/kg 5HT1B  (Anthony et al. 2000)
PXT DRN Sprague Dawley rat ISH 56 d 5mg/kg 5HT1B 0 (Anthony et al. 2000)
FLX P/FC Sprague Dawley rat PCR 21 d 10mg/kg 5HT2C  (Barbon et al. 2011)
FLX HC Sprague Dawley rat PCR 21 d 10mg/kg 5HT2C  (Barbon et al. 2011)
DR: Dorsal raphe; HC: Hippocampus; DRN: Dorsal raphe nucleus; P/FC: Prefrontal cortex; ISH: In situ hybridization; 0: no changes observed; 
: upregulation observed; : downregulation observed
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Considering findings from studies focusing on 
the effect of chronic SSRI treatment on BDNF ex-
pression, FLX failed to alter BDNF levels in a 3-week 
long chronic treatment in rats in doses of 10 and 11 
mg/kg (Hanson et al. 2011; Larsen et al. 2008), but 
another study showed elevations with FLX (10mg/kg) 
treatment following a similar treatment protocol in the 
HC and P/FC and after a one-week washout period the 
expression level was still significantly higher than basal 
levels (Musazzi et al. 2009). At the same time, the lower 
dose of 5 mg/kg in rats administered for 2 weeks in-
duced elevated BDNF expression in the frontal cortex 
(FC), but not in the HC (Rogóż et al. 2017). The same 
study examined the effects in the same time period of 
escitalopram (ESCIT) (10mg/kg) and demonstrated 
an upregulation in the HC but no changes in the FC 
(Rogóż et al, 2017). Another study showed an upreg-
ulation following 3-week FLX (10mg/kg) treatment 
(Musazzi et al. 2009). SER, after treatment for 3 weeks 
with a 10 mg/kg dose in rats, increased mRNA levels 
of both BDNF and its receptor trkB, in the HC and 
FC (Nibuya, Morinobu, and Duman 1995). See Table 
3 for a summary of the reviewed studies.
Effects of chronic SSRI administration on 
the expression of genes related to GABA 
neurotransmission
Dysfunctions of the GABAergic system are proposed 
to be associated with mood disorders. The GAB-
Aergic hypothesis by Emrich (Emrich et al. 1980) 
proposes a lack of GABA in the brain as a potential 
contributing factor in the background of mood dis-
orders suggesting that elevated levels in the brain 
might be of therapeutic relevance in affective symp-
tomatology. We only found one study reporting on 
mRNA expression of glutamic acid decarboxylase 
(GAD), the enzyme involved in GABA synthesis, 
which fulfilled our search criteria. SER in rats with 
a dose of 10 mg/kg downregulated the expression of 
GAD in the P/FC, nucleus accumbens (NAcc), olfac-
tory tubercle (OT) and the thalamic reticular nucleus 
(TRN) (Giardino et al. 1996), suggesting decreased 
GABA synthesis in these regions following treat-
ment. This result, however, is contradictory because 
in depressed humans GABA deficits normalized af-
ter SSRI intake (Sanacora et al. 2002) and it also 
opposes the original hypothesis. We didn’t find any 
further transcriptomic studies that could confirm or 
debate these findings, suggesting that studies would 
be needed to deepen our understanding concerning 
the involvement of GABA in mood disorders and 
their treatment. See Table 4 for an overview of the 
discussed result.
Effect of chronic SSRI administration  
on the expression of genes related  
to the glutamate system
Glutamate is rising as a prime target of interest in the 
treatment of several psychiatric disorders including 
major depression, especially considering the approval 
Table 3  Expression changes of neuroplasticity factors
Medication Region Species Method Time Daily dose Result Reference
FLX HC Sprague Dawley rat ISH 21 d 10mg/kg BDNF 0 (Larsen et al. 2008)
FLX HC Wistar rats PCR 14 d 5mg/kg BDNF 0 (Rogóż et al. 2017)
FLX FC Wistar rats PCR 14 d 5mg/kg BDNF  (Rogóż et al. 2017)
ESCIT HC Wistar rats PCR 14 d 10mg/kg BDNF  (Rogóż et al. 2017)
ESCIT FC Wistar rats PCR 14 d 10mg/kg BDNF 0 (Rogóż et al. 2017)
FLX HC Sprague Dawley rat PCR 21 d 10 mg/kg BDNF  (Musazzi et al. 2009)
FLX P/FC Sprague Dawley rat PCR 21 d 10 mg/kg BDNF  (Musazzi et al. 2009)
SER FC Sprague Dawley rat Northern blot 21 d 10 mg/kg BDNF  (Nibuya et al. 1995)
SER HC Sprague Dawley rat Northern blot 21 d 10 mg/kg BDNF  (Nibuya et al. 1995)
FLX HC Sprague Dawley rat ISH 21 d 11 mg/kg BDNF 0 (Hanson, Nemeroff, and Owens 2011)
SER FC Sprague Dawley rat Northern blot 21 d 10 mg/kg trkB  (Nibuya et al. 1995)
SER HC Sprague Dawley rat Northern blot 21 d 10 mg/kg trkB  (Nibuya et al. 1995)
HC: Hippocampus; P/FC: Prefrontal cortex; FC: Frontal cortex; ISH: In situ hybridization; 0: no changes observed; : upregulation observed; 
: downregulation observed
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of esketamine as a treatment in treatment resistant 
depression (www.jnj.com, accessed on the 28th of 
February, 2019). In contrast to the selective serotonin 
and noradrenalin reuptake blocker venlafaxine, which 
upregulated NR2A and NR2B subunits of NMDA 
glutamate receptors after chronic treatment in the 
FC (Tamási et al. 2014), CIT (20mg/kg) for 16 days 
downregulated the mRNA expression of almost all 
NMDA-R subunits in many regions with the excep-
tion of the HC in mice, where its levels remained 
unchanged (Boyer et al., 1998). In detail, in the amyg-
dala NR1 and NR2A-B subunits were downregulated, 
whereas NR2C showed no change. NR1 and NR2A 
subunits showed downregulation in thalamus. Inves-
tigations in the striatum reported downregulation of 
NR1 and NR2A subunits but no changes in NR2B. 
Furthermore, in the cerebellum NR1 was downregu-
lated and NR2A-C showed no significant alterations. 
In summary, surprisingly, no upregulations of NMDA 
receptor subunits could have been observed in any 
of the relevant regions following chronic SSRI treat-
ment (Boyer, Skolnick, and Fossom 1998). All this 
suggests that upregulation of glutamatergic genes 
is not the main mechanism through which SSRIs 
exert their antidepressant properties. See Table 4 for 
detailed results.
CONCLUSIONS
Transcriptomic changes after chronic treatment could 
be orientating in uncovering the hidden mechanism 
of action of SSRI antidepressants. The current stud-
ies, however, rather demonstrate just how broad the 
spectrum of molecular mechanism of chronic SSRI 
treatments may be, in contrast to their similar initial 
effects. In the serotonergic system, 5-HTT expression 
showed mostly no change, while TPH2 mRNA was 
downregulated in some brain regions including the 
DRN. Serotonin receptor gene expression was vari-
able. Chronic CIT treatment downregulated 5-HT1A 
receptors, which corresponds to the desensitization 
of the autoregulatory feedback mechanism, but FLX 
and SER downregulated 5-HT1B, with the former 
lacking effects at 5-HT1A in the DRN. FLX and CIT 
seemed to complement each other’s effect in the HC 
and FC, with FLX more reliably inducing BDNF ex-
pression elevations in the FC and CIT in the HC at 
least in the discussed transcriptomic studies. Only 
SER was able to induce upregulations of both BDNF 
and its receptor in the two regions. With GAD and 
NMDA receptor expressions unchanged or rather 
downregulated, GABAergic and glutamatergic mech-
anisms also seem to be contradictory to the many 
Table 4  Expression changes related to the neurotransmitter GABA and glutamate
Medication Region Species Method Time Daily dose Result Reference
SER P/FC Sprague Dawley rat ISH 28 d 10 mg/kg GAD  (Giardino et al. 1996)
SER NAcc Sprague Dawley rat ISH 28 d 10 mg/kg GAD  (Giardino et al. 1996)
SER OT Sprague Dawley rat ISH 28 d 10 mg/kg GAD  (Giardino et al. 1996)
SER TRN Sprague Dawley rat ISH 28 d 10 mg/kg GAD  (Giardino et al. 1996)
CIT HC NIH-Swiss mice ISH 16 d 20 mg/kg NR1 0 (Boyer et al. 1998)
CIT HC NIH-Swiss mice ISH 16 d 20 mg/kg NR2A-C 0 (Boyer et al. 1998)
CIT Amygdala NIH-Swiss mice ISH 16 d 20 mg/kg NR1  (Boyer et al. 1998)
CIT Amygdala NIH-Swiss mice ISH 16 d 20 mg/kg NR2A-B  (Boyer et al. 1998)
CIT Amygdala NIH-Swiss mice ISH 16 d 20 mg/kg NR2C 0 (Boyer et al. 1998)
CIT Thalamus NIH-Swiss mice ISH 16 d 20 mg/kg NR1  (Boyer et al. 1998)
CIT Thalamus NIH-Swiss mice ISH 16 d 20 mg/kg NR2A  (Boyer et al. 1998)
CIT Striatum NIH-Swiss mice ISH 16 d 20 mg/kg NR1  (Boyer et al. 1998)
CIT Striatum NIH-Swiss mice ISH 16 d 20 mg/kg NR2A  (Boyer et al. 1998)
CIT Striatum NIH-Swiss mice ISH 16 d 20 mg/kg NR2B 0 (Boyer et al. 1998)
CIT Cerebellum NIH-Swiss mice ISH 16 d 20 mg/kg NR1  (Boyer et al. 1998)
CIT Cerebellum NIH-Swiss mice ISH 16 d 20 mg/kg NR2A-C 0 (Boyer et al. 1998)
P/FC: Prefrontal cortex; NAcc: Nucleus accumbens; HC: Hippocampus; OT: Olfactory tubercle; TRN: Thalamic reticular nucleus; ISH: In situ 
hybridization; 0: no changes observed; : upregulation observed; : downregulation observed
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theories involving these neurotransmitter systems 
in depression. While we have to mention among the 
many limitations that the reviewed studies employed 
different rat strains, and that mRNA levels not neces-
sarily represent protein levels, these results point to 
the enormous heterogeneity of action mechanisms 
behind the seemingly “homogeneous” class of SSRI 
ADs. In addition, the results of this review also under-
line the need for the development of novel ADs with 
more reliable clarity in their actions on a molecular 
level and raises the possibility of a novel grouping of 
antidepressants based rather on their chronic molec-
ular changes, than on their initial effects.
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Krónikus szelektív szerotoninvisszavétel-gátló kezelés hatására 
bekövetkező transzkripciós változások: az állatkísérletek  
áttekintése 
A közlemény a szelektív szerotoninvisszavétel-gátló (SSRI) antidepresszívumok hatására 
bekövetkező transzkriptomikai változásokat tekinti át. Célunk az volt, hogy összefoglaljuk a 
különböző agyterületeken krónikus kezelések hatására bekövetkező, a génexpressziós válto-
zások vizsgálatának leggyakrabban használt módszereivel – így Northern blottal, in situ hibri-
dizációval, kvantitatív reverz transzkriptáz-polimeráz láncreakcióval (qRT-PCR), microarray-jel 
és a RNS szekvenálással – végzett kísérletek eredményeit. Annak ellenére, hogy a szerotonerg 
rendszer génjeiben krónikus SSRI kezelés hatására mRNS szinten mérhető változások voltak 
megfigyelhetők, a szerotonintranszporter szintje legtöbbször változatlan maradt. Ugyanak-
kor a triptofán-hidroxiláz-2 downregulálódott a szerotonerg magokban és upregulálódott 
a középagyi területeken. A szerotoninreceptorokat érintő változások nem mutattak egységes 
képet, és a leírt változások valószínűleg törzstől, hatóanyagtól, illetve a különböző vizsgált 
agyterületektől függő hatásokat is tükröznek. A legtöbb krónikus kezelés növelte az agy-ere-
detű neurotróf faktor expresszióját. A GABA- valamint a glutamátreceptorok génjei szintén 
heterogén változásokat mutatnak; meglepő módon az NMDA receptorok downregulációja 
volt megfigyelhető a depresszió és a stresszreakciók kialakításában részt vevő olyan agyterüle-
teken, mint például a striatum és az amygdala területén. A fenti kutatások áttekintése számos 
eltérésre hívja fel a figyelmet, és hangsúlyozza a vizsgált agyterülettől és SSRI gyógyszertől 
is függő hatások heterogenitását. Mindeközben azonban az eredmények felvetik annak 
lehetőségét is, hogy az antidepresszívumokat – akut hatásmechanizmusuk helyett – talán 
célszerűbb volna krónikus molekuláris hatásaik alapján csoportosítani.
Kulcsszavak: SSRI, BDNF, patkány, transzkriptomika, 5-HTT
